Alumis Inc. (ALMS) is a prominent player in the aluminum sector, specializing in the development and commercialization of high-performance aluminum solutions for automotive, aerospace, and construction industries. By harnessing proprietary technologies and a commitment to sustainability, Alumis not only drives innovation in materials science but also prioritizes environmental responsibility. The company's strong focus on research and development enables it to adapt to emerging market trends, resulting in a diverse product portfolio designed to meet the dynamic needs of its clients. With a commitment to operational excellence, Alumis is well-positioned to achieve sustained growth and deliver long-term value for investors. Show more

280 EAST GRAND AVENUE, SOUTH SAN FRANCISCO, CA, UNITED STATES, 94080, South San Francisco, CA, 94080, USA

BIOTECHNOLOGY

HEALTHCARE

Market Cap

3.257B

52 Wk Range

$3.76 - $31.35

Previous Close

$25.37

Open

$25.51

Volume

991,904

Day Range

$24.85 - $26.00

Enterprise Value

2.748B

Cash

63.89M

Avg Qtr Burn

-87.08M

Insider Ownership

0.55%

Institutional Own.

Qtr Updated

03/31/26

Only showing assets and stage. See catalyst data with a free or premium account. Unlock more data with a free account.

Drug & Indication	Stage & Event	Catalyst Date
ESK-001 Details Moderate-to-severe plaque psoriasis	NDA Submission	Some catalyst date You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details.Sign up now.
ESK-001 Details Systemic lupus erythematosus	Phase 2b Data readout	Some catalyst date You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details.Sign up now.
A-005 Details Multiple sclerosis	Phase 2 Initiation	Some catalyst date You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details.Sign up now.
Lonigutamab (IGF-1R Antibody) Details Thyroid Eye Disease	Phase 1/2 Update	Some catalyst date You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details.Sign up now.